Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MIRCEA O BADARA

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1801877865
CMS profile
500107
Location
NEW BRITAIN, CT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$3,530.76

162 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,350.87 160
Education $179.89 2

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MIRCEA O BADARA

NPI 1801877865 · CMS profile ID 500107

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

NEW BRITAIN, CT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1801877865?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MIRCEA O BADARA, NPI 1801877865, CMS profile ID 500107. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1801877865?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MIRCEA O BADARA, NPI 1801877865, CMS profile ID 500107. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1801877865?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MIRCEA O BADARA, NPI 1801877865, CMS profile ID 500107, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1801877865?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

162 matching records · $3,530.76 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 162 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 162.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $24.2509/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212866750 CMS
Axsome Therapeutics, Inc. $25.9509/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235515564 CMS
3B Medical, Inc. $22.0909/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1253251091 CMS
GlaxoSmithKline, LLC. $20.5508/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191505176 CMS
GlaxoSmithKline, LLC. $13.5308/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190624192 CMS
GlaxoSmithKline, LLC. $12.3208/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191581700 CMS
GlaxoSmithKline, LLC. $17.9508/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191554001 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.4408/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223771187 CMS
Axsome Therapeutics, Inc. $22.2408/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235465540 CMS
AstraZeneca Pharmaceuticals LP $25.9208/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206361905 CMS
Axsome Therapeutics, Inc. $17.0108/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235465492 CMS
Avadel CNS Pharmaceuticals, LLC $29.8808/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208531633 CMS
GlaxoSmithKline, LLC. $24.0608/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191354463 CMS
Verona Pharma, Inc. $26.9908/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233768117 CMS
GlaxoSmithKline, LLC. $14.6707/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191066975 CMS
GlaxoSmithKline, LLC. $2.2007/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191575185 CMS
AstraZeneca Pharmaceuticals LP $23.3507/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206557599 CMS
AstraZeneca Pharmaceuticals LP $23.4807/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206421599 CMS
Avadel CNS Pharmaceuticals, LLC $8.0807/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208531631 CMS
Axsome Therapeutics, Inc. $27.1407/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235412360 CMS
Axsome Therapeutics, Inc. $14.5107/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235412364 CMS
GlaxoSmithKline, LLC. $19.7307/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190346728 CMS
Takeda Pharmaceuticals U.S.A., Inc. $29.1407/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223771195 CMS
AstraZeneca Pharmaceuticals LP $23.6207/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206158118 CMS
GENZYME CORPORATION $21.9207/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233405766 CMS
Avadel CNS Pharmaceuticals, LLC $5.4707/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208531629 CMS
Mallinckrodt Hospital Products Inc. $14.9907/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211950227 CMS
Pulmonx Corporation $25.4407/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1199535713 CMS
GlaxoSmithKline, LLC. $25.0007/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190467587 CMS
Avadel CNS Pharmaceuticals, LLC $22.2407/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208531627 CMS
AstraZeneca Pharmaceuticals LP $24.0107/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206326758 CMS
GlaxoSmithKline, LLC. $23.3006/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191261251 CMS
Axsome Therapeutics, Inc. $27.1806/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235747616 CMS
GlaxoSmithKline, LLC. $9.1706/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190663811 CMS
GlaxoSmithKline, LLC. $7.2406/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191519726 CMS
AstraZeneca Pharmaceuticals LP $15.1706/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206814139 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $21.5606/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223060768 CMS
HARMONY BIOSCIENCES LLC $41.9206/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222405057 CMS
GlaxoSmithKline, LLC. $26.6706/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191722630 CMS
AstraZeneca Pharmaceuticals LP $24.4506/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206421429 CMS
Viatris Specialty LLC $14.5906/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238515799 CMS
GlaxoSmithKline, LLC. $3.2406/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190418535 CMS
GlaxoSmithKline, LLC. $17.6206/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190464475 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.1406/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223771185 CMS
Amgen Inc. $26.1906/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228338552 CMS
AstraZeneca Pharmaceuticals LP $23.7106/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207192719 CMS
GENZYME CORPORATION $28.9506/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233405744 CMS
Lilly USA, LLC $20.5606/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186754749 CMS
Mallinckrodt Hospital Products Inc. $37.4306/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211950225 CMS
Verona Pharma, Inc. $28.4705/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233768119 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $175.31 13
PY2020 $92.66 6
PY2021 $1,795.09 93
PY2022 $2,319.82 125
PY2023 $2,413.94 125
PY2024 $3,278.14 147
PY2025 $3,530.76 162

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $415,289.17 38
PY2024 Principal investigator $356,161.99 41
PY2023 Principal investigator $217,952.31 23

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

38 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 CSL Behring $1,500.00 12/22/2025 Non-covered Recipient Entity
Innovo Research
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1252670234
Principal investigator 1 CSL Behring $1,750.00 12/22/2025 Non-covered Recipient Entity
Innovo Research
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1252670236
Principal investigator 1 CSL Behring $2,500.00 12/22/2025 Non-covered Recipient Entity
Innovo Research
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1252670238
Principal investigator 1 CSL Behring $2,750.00 12/22/2025 Non-covered Recipient Entity
Innovo Research
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1252670240
Principal investigator 1 CSL Behring $12,500.00 12/22/2025 Non-covered Recipient Entity
Innovo Research
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1252670242
Principal investigator 1 Genentech, Inc. $3,306.00 12/12/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615602
Principal investigator 1 Genentech, Inc. $2,250.00 11/26/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615553
Principal investigator 1 Genentech, Inc. $400.00 10/15/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615538
Principal investigator 1 Genentech, Inc. $62,201.00 09/24/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615469
Principal investigator 1 AstraZeneca Pharmaceuticals LP $50,748.97 08/22/2025 Non-covered Recipient Entity
INNOVO RESEARCH LLC
a phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure No dispute reported 06/30/2026 1185551177
Principal investigator 1 AstraZeneca Pharmaceuticals LP $23,750.00 08/07/2025 Non-covered Recipient Entity
INNOVO RESEARCH LLC
Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD No dispute reported 06/30/2026 1185551181
Principal investigator 1 Genentech, Inc. $456.26 07/02/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615434
Principal investigator 1 Genentech, Inc. $400.00 07/02/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615441
Principal investigator 1 Genentech, Inc. $5,194.00 07/02/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615462
Principal investigator 1 Genentech, Inc. $1,274.00 06/18/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615352
Principal investigator 1 Genentech, Inc. $243.54 06/13/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615219
Principal investigator 1 Genentech, Inc. $728.00 06/13/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615356
Principal investigator 1 Genentech, Inc. $120.97 05/30/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615309
Principal investigator 1 Genentech, Inc. $1,508.00 05/16/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615382
Principal investigator 1 Genentech, Inc. $58,741.00 05/16/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615397
Principal investigator 1 Genentech, Inc. $3,039.28 05/07/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615329
Principal investigator 1 Genentech, Inc. $207.65 04/30/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615234
Principal investigator 1 Genentech, Inc. $3,458.00 03/26/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211614944
Principal investigator 1 Genentech, Inc. $5,961.00 03/05/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211614829
Principal investigator 1 Genentech, Inc. $767.71 02/26/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615003
Principal investigator 1 Genentech, Inc. $3,081.47 02/19/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615132
Principal investigator 1 Genentech, Inc. $1,750.00 02/14/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211614961
Principal investigator 1 Genentech, Inc. $1,987.00 02/12/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615086
Principal investigator 1 Genentech, Inc. $245.14 02/05/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211614929
Principal investigator 1 Genentech, Inc. $37,676.00 02/05/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615040
Principal investigator 1 Genentech, Inc. $419.18 01/31/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211614867
Principal investigator 1 Genentech, Inc. $122.57 01/31/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211614954
Principal investigator 1 Genentech, Inc. $122.57 01/31/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615076
Principal investigator 1 Genentech, Inc. $655.66 01/31/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615091
Principal investigator 1 Genentech, Inc. $3,232.00 01/29/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615120
Principal investigator 1 Genentech, Inc. $4,048.00 01/22/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211614906
Principal investigator 1 Genentech, Inc. $10,006.00 01/14/2025 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211615045
Principal investigator 1 AstraZeneca Pharmaceuticals LP $106,188.20 01/03/2025 Non-covered Recipient Entity
INNOVO RESEARCH LLC
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure No dispute reported 06/30/2026 1185551179